Furthermore, the levels of inflammation and fibrosis gene markers also showed that pretreatment with APS could alleviate the renal injury in an in vitro hypertensive model by regulating the TGF-β/ILK pathway. This evidence concerns the gene TGFB1 and autoimmune polyendocrinopathy.